Van Der Doelen MJ, Kuppen MCP, Jonker MA, et al. Real world lessons for optimal selection of patients with bone metastatic castration-resistant prostate cancer for radium-223 therapy. EMUC 2017, P049.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker